Saturday 17 October 2026 Export AIM’s income statement to Excel — free account

AIM ImmunoTech Inc.

AIM ImmunoTech Inc.’s revenue for fiscal 2025 (year ended December 2025) was $88,000.00, down 48.2% from fiscal 2024. In the quarter to June 2026, revenue grew 4.00%, EPS grew 94.0% and free cash flow fell 167.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.17 0.00 0.00%

Follow AIM

Alert me

Market cap: $6.8M
P/E: 0.0×
Fwd P/E: −0.6×
Dividend yield: —
F-score: 3/9
Altman Z: −113.91
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.01

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	4	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 6.79

Revenue 0.10

Net Income (14.27)

Free Cash Flow (14.62)

Net Debt (9.96)

Current Ratio 2.11

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.57)

P/S ratio 30.63

P/B ratio 0.38

Past 5Y EPS Growth —

This Y EPS Growth 90.02%

Next Y EPS Growth 37.21%

Next Y revenue growth (15.91%)

Next 5Y EPS Growth 58.64%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 26.22%

10-year low 10-year high

P/B against its own 10 years 4.95%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	13	4	3	10
Receivables	1	—	0	—
Inventory	—	—	—	—
Other	—	—	—	—
	15	4	3	10

	2023	2024	2025	Q'26
Payables	6	6	2	0
ST’ Debt	—	—	—	—
Other	—	—	—	—
	9	10	6	5

Compound Annual Growth %

	10y	5y	3y
Sales	(4.05%)	(11.60%)	(14.54%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Sep	Dec	Year
’26	—	—	—
’25	0	0	0
’24	0	0	0
’23	0	0	0
’22	0	0	0
’21	0	0	0
’20	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(5)	—	—	—
’25	(2)	(2)	(5)	(2)	(11)
’24	(5)	(3)	(3)	(4)	(15)
’23	(4)	(2)	(6)	(10)	(21)
’22	(3)	(2)	(5)	(6)	(16)
’21	(3)	(2)	(3)	(6)	(14)
’20	(3)	(1)	(3)	(3)	(10)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(5)	—	—	—
’25	(2)	(2)	(5)	(2)	(11)
’24	(5)	(3)	(3)	(4)	(15)
’23	(4)	(2)	(6)	(10)	(22)
’22	(3)	(2)	(5)	(3)	(12)
’21	(3)	(1)	(4)	(6)	(14)
’20	(3)	(1)	(3)	(3)	(11)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.69)	(0.22)	—	—	—
’25	(5.00)	(3.68)	—	(0.44)	(8.62)
’24	(12.00)	(3.00)	(6.00)	(10.00)	(31.00)
’23	(8.00)	(10.00)	(16.00)	(26.00)	(60.00)
’22	(8.00)	(10.00)	(13.00)	(9.00)	(40.00)
’21	(8.00)	(12.00)	(8.00)	(12.00)	(40.00)
’20	(22.00)	(11.00)	(8.00)	(9.00)	(45.00)

Fiscal quarters ending in the months shown.

value withheld pending a data check

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	2,774.01	1,280.31	640.16	36.86	49.47	82.44	28.13	29.10	15.52	1.04	Analyst estimates 2026–2028 Powerpack
	High	11,266.73	3,968.96	2,774.01	1,451.02	689.62	296.80	133.85	81.47	60.14	34.92
People
People	Employees	34	27	33	26	23	21	22	28	23	21
	Revenue/emp, $m	0.00	0.02	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.00
Income, $m
Income, $m	Revenue	0	0	0	0	0	0	0	0	0	0
	Gross margin, %	(1,104.35)	(170.71)	(140.87)	(537.86)	(394.48)	(529.63)	100.00	79.21	81.76	(45.45)
	EBT	(8)	(8)	(10)	(9)	(14)	(19)	(19)	(29)	(17)	(14)
	EBT margin, %	(8,154.35)	(1,889.93)	(2,677.66)	(6,717.14)	(8,834.36)	(14,168.15)	(13,790.78)	(14,337.62)	(10,188.24)	(15,861.36)
	Net income	(8)	(8)	(10)	(9)	(14)	(19)	(19)	(29)	(17)	(14)
	Depreciation	1	1	1	1	1	1	0	0	1	2
Per share, $
Per share, $	Revenue	18.40	67.23	36.70	3.85	0.51	0.29	0.29	0.42	0.30	0.05
	Earnings	(1,497.80)	(1,277.53)	(969.16)	(211.79)	(45.00)	(40.00)	(40.00)	(60.00)	(31.00)	(8.62)
	Cash flow	(1,476.00)	(1,221.69)	(1,064.00)	(249.09)	(32.56)	(29.50)	(33.52)	(43.77)	(26.58)	(6.77)
	Capex	(90.80)	(10.62)	92.30	(10.03)	(1.87)	(0.82)	7.55	(1.11)	(0.99)	(0.23)
	Free cash flow	(1,566.80)	(1,232.31)	(971.70)	(259.12)	(34.43)	(30.32)	(25.97)	(44.88)	(27.57)	(7.00)
	Book value	3,099.60	1,338.92	517.40	369.29	192.51	120.15	80.06	21.06	(2.36)	(6.04)
	Shares, m	0	0	0	0	0	0	0	0	1	2
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	160.04	22.22	20.93	5.02	339.14	312.90	105.78	112.00	63.93	20.23
	P/B	0.95	1.12	1.48	0.15	0.91	0.75	0.39	2.37	0.00	0.00
	EV/Sales	96.29	21.60	22.82	(1.69)	112.79	(42.08)	(130.37)	51.14	42.73	(1.20)
	EV/FCF	(1.13)	(1.18)	(0.86)	0.07	(1.68)	0.40	1.47	(0.47)	(0.47)	0.01
Cash, $m
Cash, $m	Operating cash flow	(7)	(8)	(11)	(9)	(10)	(14)	(16)	(21)	(15)	(11)
	Capex	0	0	1	0	(1)	0	4	(1)	(1)	0
	Free cash flow	(8)	(8)	(10)	(9)	(11)	(14)	(12)	(22)	(15)	(11)
Balance, $m
Balance, $m	Working capital	5	1	(1)	9	39	50	35	6	(5)	(3)
	Total debt	—	2	3	6	2	0	1	—	—	1
	Net debt	(6)	0	1	(3)	(37)	(48)	(34)	(13)	(4)	(2)
	Shareholders’ equity	15	9	5	13	61	57	38	10	(1)	(10)
Returns, %
Returns, %	ROA	(36.00)	(49.93)	(70.06)	(54.36)	(33.75)	(31.28)	(39.61)	(96.75)	(123.76)	(194.00)
	ROIC	(89.59)	(84.63)	(122.49)	(71.40)	(38.81)	(134.97)	(252.22)	0.00	0.00	0.00
	ROE	(41.83)	(68.25)	(141.63)	(105.44)	(39.33)	(32.77)	(41.40)	(122.42)	(421.26)	251.38

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SKYE Skye Bioscience, Inc.	$7.0M	— (loss-making)	—	−34.71% (below 0%: shrinking)	n/m	+34.84% (above 0%: growing)	72.71%	0.00%	Compare
BCLI Brainstorm Cell Therapeutics Inc.	$7.0M	— (loss-making)	—	—	n/m	+74.44% (above 0%: growing)	0.00%	0.00%	Compare
CLGN CollPlant Biotechnologies Ltd. Sponsored ADR	$7.0M	— (loss-making)	— (loss-making)	−39.66% (below 0%: shrinking)	n/m	+5.08% (above 0%: growing)	(422.22%)	(2,437.96%)	Compare
NIKI Niki BioSolutions, Inc.	$6.9M	— (loss-making)	31.9×	−32.36% (below 0%: shrinking)	+69.51% (above 0%: growing)	+58.14% (above 0%: growing)	(154.22%)	0.00%	Compare
AIM AIM ImmunoTech Inc.	$6.8M	— (loss-making)	— (loss-making)	+4.00% (above 0%: growing)	n/m	−167.46% (below 0%: shrinking)	80.77%	(13,511.54%)
SYBX Synlogic, Inc.	$6.7M	— (loss-making)	— (loss-making)	−95.40% (below 0%: shrinking)	n/m	−277.87% (below 0%: shrinking)	100.00%	0.00%	Compare
FBLG FibroBiologics Inc.	$6.7M	— (loss-making)	—	—	n/m	+21.59% (above 0%: growing)	—	0.00%	Compare
ACXP Acurx Pharmaceuticals, Inc.	$6.5M	— (loss-making)	—	—	n/m	−2.36% (below 0%: shrinking)	—	0.00%	Compare
TCRT Alaunos Therapeutics, Inc.	$6.4M	— (loss-making)	— (loss-making)	+200.00% (above 0%: growing)	n/m	+57.20% (above 0%: growing)	100.00%	0.00%	Compare
Median of peers	$6.8M	—	—	−34.71%	—	+28.22%	36.36%	0.00%

All 614 Biotechnology stocks →

AIM ImmunoTech Inc. (AIM) key facts

Concern: AIM ImmunoTech Inc.’s revenue for fiscal 2025 (year ended December 2025) was $88,000.00, down 48.2% from fiscal 2024.
AIM ImmunoTech Inc. (AIM) is a Biotechnology company in the Healthcare sector, listed on NYSE American.
As of October 16, 2026, AIM traded at $0.17, a market capitalization of $6.8 million.
Return on equity was 251.4% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −113.91 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.